FEP $34.52 -0.3046%
CCEL $4.62 5.9633%
CVBF $11.00 1.2431%
IPW $0.59 0.0169%
MHC.L $21.00 1432.85%
PDTC3.SA $2.47 -8.1784%
0455.HK $0.20 0.4975%
0419.HK $0.12 -1.6%
BOCH.L $223.00 1.3636%
TGR.L $35.00 -2.2346%
MIG4.L $74.50 4.1958%
CSV $27.93 -0.2679%
GENC $14.17 3.5819%
0MCG.L $6.86 -0.676%
NRZ-PC $20.40 0%
0242.HK $1.39 -0.7143%
3326.HK $0.20 -3.3654%
GFGB.L $46.61 0.6533%
0868.HK $13.12 -1.9432%
DCPH $13.63 -0.8727%
KITW.L $309.00 5.4608%
CHNA $17.92 0.0419%
SNV-PD $19.47 1.4068%
URR $14.01 0%
AATC $4.00 0%
7322.HK $6.60 0%
0440.HK $21.00 -0.9434%
OKE $63.10 0.4297%
0737.HK $1.97 -1.5%
HTWD.L $55.55 0.4702%
JSG.L $123.80 -0.1613%
ROK $270.03 0.2674%
NAVI $14.74 -0.4054%
SLN.L $535.00 0%
GTX $7.95 -1.7305%
0LS8.L $71.59 -0.4035%
KNSL $328.50 -0.9588%
RBAC $10.02 0%
XPO $46.96 -0.1701%
DWAC $13.58 -2.5305%
0P00017UWR.L $16 864.10 0.2461%
8269.HK $0.11 0%
SPX5.L $330.60 0.3552%
IWF $246.96 -0.8113%
ARE $118.79 -1.3454%
ODET.PA $1 578.00 -0.1266%
1300.HK $0.38 0%
TMC $0.72 -2.0675%
SCHO $48.74 -0.1641%
CBBB.PA $14.18 -0.0747%
2399.HK $0.52 0%
2225.HK $2.45 0%
MU $60.52 -1.7692%
GUSA $35.73 0%
QMN $24.84 0%
SLNO $4.17 -0.7143%
FVAL $45.52 -0.7003%
SUSL $71.29 -0.5302%
1186.HK $6.36 -6.6079%
HGT.L $363.50 1.2535%
AURA33.SA $36.86 2.3889%
YELP $29.56 -0.8054%
SCMAU $10.87 0%
SGZ.L $16.50 0%
ERF $13.97 -0.7107%
HIBS $6.15 3.3613%
UGRO $1.33 2.3077%
1540.HK $0.40 -1.2346%
KMI $16.75 0.2695%
AGRI $0.50 -7.2037%
QFTA-UN $10.19 0%
FCSS.L $224.50 -1.3187%
0294.HK $1.31 -2.963%
UC97.L $15.09 -0.642%
JPEH.L $48.87 0%
HFBL $17.99 15.2466%
IHRT $2.53 -7.156%
1217.HK $0.01 0%
HUW.L $160.75 0.4688%
0QK8.L $42.60 -1.825%
MG $7.03 1.8841%
PRIE.L $2 303.20 0.5983%
A5G.IR $3.89 2.2632%
1085.HK $2.38 0.422%
CMS $61.59 0.065%
TWCB $10.11 0.0991%
KINZU $10.23 0%
0377.HK $1.10 0%
HBANN $25.09 0%
PEGRW $0.07 18.9744%
LSIL.L $5.49 -3.5149%
SBRE.L $120.80 2.027%
NHICW $0.01 0%
AAON $94.16 -1.7016%
NNY $8.61 0.0465%
NUE $138.22 0.5163%
CZNC $17.89 1.3314%
ENVIW $0.65 0%
FRUE.L $45.57 0%
1736.HK $0.03 -6.25%
Eng
Логотип
Eng
Лого

Pharma Mar, S.A. PHM.MC

$35.74

-$0.3 (-0.83%)
На 18:05, 12 мая 2023

Ранг: 2

Ранг - это оценка кредитоспособности корпорации.

Ключевые показатели

  • Marketcap

    646618168.00000000

  • week52high

    74.86

  • week52low

    35.30

  • Revenue

    196343000

  • P/E TTM

    23

  • Beta

    0.09541900

  • EPS

    2.53000000

  • Last Dividend

    0.65000000

  • Next Earnings Date

    25 июл 2023 г. в 10:59

Описание компании

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.

Свежие комментарии

Оставьте свой голос

Анонимное голосование

Будет ли рост российского рынка к концу года?

  • Да

    87%

  • Нет

    12%

Проголосовал 8 человек